It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Clinical Trials

Head and neck surgeon Kerstin Stenson, MD

When you come to Rush University Cancer Center for care, you may have the opportunity to participate in a clinical trial. Below you’ll find clinical trials available at Rush for specific cancers. Talk to your clinician to determine if a clinical trial is right for you.

Clinical Trial Categories

Bladder Cancers Brain Tumors Breast Cancer
Cancer of Unknown Primary Gastrointestinal Cancers Gynecologic Cancers
Head and Neck Cancers Kidney Cancers Leukemia
Liver, Biliary and Pancreatic Cancers Lung and Chest Tumors Lymphoma
Melanoma and Soft Tissue Cancers Myeloma Pediatric Cancers
Prostate Cancer Sarcomas Testicular Cancer

 

Bladder Cancers

Drug Treatment Study for Patients with Advanced Cancers
A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination With atezolizumab in patients with selected incurable cancers.

Urothelial Carcinoma Treatment Stud
A phase III randomized, controlled clinical trial of pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy in subjects with advanced or metastatic urothelial carcinoma.

Back to top of page

 

Brain Tumors

Glioblastoma Drug Treatment Study
A phase II/III randomized trial of veliparib or placebo In combination with adjuvant temozolomide In newly diagnosed glioblastoma with MGMT promoter hypermethylation.

Meningioma Drug Treatment Study
A study looking at targeted therapy according to tumor markers for people with meningiomas.

Patients With Newly Diagnosed Glioblastoma Treatment Study
Randomized phase II trial of hypofractionated dose-escalated photon IMRT or proton beam therapy versus conventional photon irradiation with concomitant and adjuvant temozolomide in patients with newly diagnosed glioblastoma.

Patients With Selected Advanced Cancers Treatment Study
A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers.

Treatment Study for Radionecrosis after Radiosurgery for Brain Metastases
Randomized phase II study: Corticosteroids + bevacizumab vs. oorticosteroids + placebo (BeSt) for radionecrosis after radiosurgery for brain metastases.

Back to top of page

 

Breast Cancer

Advanced Breast Cancer Treatment Study
Study assessing the efficacy and safety of alpelisib plus fulvestrant in men and postmenopausal women with advanced breast cancer which progressed on or after aromatase inhibitor treatment.

BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Treatment Study
Olaparib as adjuvant treatment in patients with BRCA mutated high risk HER2 negative primary breast cancer (OlympiA).

Diet and Physical Activity Behaviors of Breast Cancer Survivors Study
Diet, activity and lifestyle (DiAL).

Drug Combination Treatment Study for Patients with Advanced or Metastatic Breast Cancer
An open-label phase 2 study of MLN0128 (a TORC1/2 inhibitor) in combination with fulvestrant in women with ER-positive/HER2-negative advanced or metastatic breast cancer that has progressed during or after aromatase inhibitor therapy.

Drug Treatment Study for Patients with Advanced Cancers
A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination With atezolizumab in patients with selected incurable cancers.

Evaluative Everolimus with Endocrine Therapy
Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk hormone receptor-positive and HER2/neu negative breast cancer.

HER2-Positive Locally Advanced/Metastatic Breast Cancer Treatment Study
A randomized, multicenter, open label study of MM-302 plus trastuzumab vs. chemotherapy of physician's choice plus trastuzumab in anthracycline naive patients with locally advanced/metastatic HER2-positive breast cancer.

Limited Metastatic Breast Cancer Treatment Study
A stage IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.

Metastatic HER2 Non-Amplified but HER2 Mutant Breast Cancer Treatment Study
A phase II study of neratinib in metastatic HER2 non-amplified but HER2 mutant breast cancer.

Metastatic Triple Negative Breast Cancer Treatment Study
A phase III, multicenter, randomized placebo-controlled study of atezolizumab (MPDL3280A) in combination with nab paclitaxel compared with placebo with nab paclitaxel for patients with Previously untreated metastatic triple negative breast cancer.

Palbociclib in HR-Positive/HER2-Normal Early Breast Cancer
Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy "PENELOPEB."

The Role of suPAR in Doxorubicin Induced Cardiomyopathy in Breast Cancer Patients
SuPAR: The role of suPAR in doxorubicin induced cardiomyopathy in breast cancer patients: Causative vs. predictor.

Study for Patients with HR+/HER2- Early Breast Cancer
A randomized phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

Treatment Study for HER2+ Breast Cancer
Phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated unresectable locally advanced or metastatic HER2+ breast carcinoma.

Treatment Study for Patients with Advanced Malignancies
A phase 1, open-label, dose-escalation study of SEA-CD40 in adult patients with advanced malignancies.

Triple-Negative Breast Cancer Drug Treatment Study
Phase III trial to evaluate the efficacy & safety of MK-3475 (pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer with ≥ 1cm residual invasive cancer or positive lymph nodes (ypN+) after neoadjuvant chemotherapy.

Undetected BRCA Mutations in Patients with Breast and Other Cancers
Can undetected familial mutations in BRCA1 and BRCA2 genes explain some cancer in BRCA non-carriers? A pilot project.

Back to top of page

 

Cancer of Unknown Primary

Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
A prospective observational trial evaluating outcomes of FoundationOne: Directed matched targeted therapy in patients with cancer of unknown primary (CUP).

Treatment Study for Patients with Rare Tumors
DART: Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.

Back to top of page

 

Gastrointestinal Cancers

Colonoscopy Research Study
R01 colonoscopy research study.

Development of Screening Test for Colorectal Cancer Study
Stool sample collection protocol for development of screening test for colorectal cancer.

Drug Treatment Study for Patients with Advanced Cancers
A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination With atezolizumab in patients with selected incurable cancers.

Locally Advanced Rectal Cancer Treatment Study
A phase II/III trial of neoadjuvant FOLFOX with selective use of combined modality chemoradiation vs preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision.

Pancreas Adenocarcinoma Treatment Study
A phase III trial evaluating both erlotinib and chemoradiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma.

Patients With Selected Advanced Cancers Treatment Study
A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers.

Rectal and Anal Carcinomas Validation Study
Prospective validation study for rectal and anal carcinomas.

Treatment Study for Non-Small Cell Lung Cancer and Adenocarcinoma
A phase 1b open-label study of PEGylated recombinant human hyaluronidase (PEGPH20) combined with pembrolizumab in subjects with selected hyaluronan-high solid tumors.

Treatment Study for Patients with Non-Small Cell Lung Cancer, Melanoma or Colorectal Cancer
A phase 1b/2, open-label, dose escalation study of entinostat in combination with pembrolizumab in patients with non-small cell lung cancer, with expansion cohorts in patients with NSCLC, melanoma, and mismatch repair-proficient colorectal cancer.

Treatment Study for Patients with Advanced Malignancies
A phase 1, open-label, dose-escalation study of SEA-CD40 in adult patients with advanced malignancies.

Back to top of page

 

Gynecologic Cancers

Adjuvant Radiation Versus Chemoradiation in Cervical Cancer Previously Treated with Surgery
Randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy.

Effect of Diet and Exercise on Ovarian Cancer Survivors
GOG 0225 -- Can diet and exercise modulate ovarian, fallopian tube and primary peritoneal cancer progress-free survival? Also known as LIvES (lifestyle Intervention for ovarian cancer enhanced survival).

Ovarian, Fallopian Tube or Peritoneal Cancer Treatment Study
A phase III study comparing olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer.

Patients With Selected Advanced Cancers Treatment Study
A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers.

PET/CT Guided Dose Steering Study for Patients With Cervical Cancer
A feasibility study of PET/CT guided dose steering in high dose rate interstitial brachytherapy for carcinoma of the uterine cervix.

Treatment Study for Patients with Ovarian, Fallopian Tube or Peritoneal Cancer
Phase II/III study of the combination of cediranib maleate and olaparib compared to cediranib or olaparib alone or standard of care chemo in patients with recurrent platinum-resistant or -refractory ovarian, fallopian tube or primary peritoneal cancer.

Undetected BRCA Mutations in Patients with Breast and Other Cancers
Can undetected familial mutations in BRCA1 and BRCA2 genes explain some cancer in BRCA non-carriers? A pilot project.

Back to top of page

 

Head and Neck Cancers

Locally Advanced Head and Neck Squamous Cell Carcinoma Treatment Study
A randomized phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma.

Patients With Selected Advanced Cancers Treatment Study
A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers.

RM-1929 and Photoimmunotherapy in Recurrent Head and Neck Cancer
A phase I multicenter, open-label, dose-escalation, combination study of RM-1929 And photoimmunotherapy in patients with recurrent HNC who in the opinion of their physician cannot be satisfactorily treated with surgery, radiation or platinum chemotherapy.

Study of INFIELD Therapy for Head and Neck Cancer
INFIELD: A prospective phase II study of involved field elective volume de-intensification for oropharyngeal and laryngeal squamous cell carcinoma treated with intensity modulated radiation therapy.

The PATHWay Study for Patients with Head and Neck Cancers
The PATHWay study: A randomized, double-blind phase II study of pembrolizumab versus placebo in patients with head and neck cancers at high risk for recurrence or low-volume residual disease.

Treatment Study for Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma
A phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiotherapy, and MK-3475 (pembrolizumab) in high-risk head and neck squamous cell carcinoma (HNSCC).

Back to top of page

 

Kidney Cancers

Advanced Clear Cell Renal Cell Carcinoma Treatment Study
A phase 1, multiple‐dose, dose‐escalation trial of PT2385 tablets, a HIF‐2α inhibitor, in patients with advanced clear cell renal cell carcinoma.

Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma Treatment Study
A single-arm, multicenter, phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic nccRCC who have not received any chemotherapy for advanced disease.

Advanced Renal Cell Carcinoma Therapy Study
Study to evaluate the safety and efficacy of study drug plus everolimus in patients with advanced renal cell carcinoma.

Drug Treatment Study for Patients with Advanced Cancers
A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination With atezolizumab in patients with selected incurable cancers.

Patients With Selected Advanced Cancers Treatment Study
A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers.

Renal Cell Carcinoma Treatment Study
Clinical trial with combination therapies in immuno-oncology in advanced renal cell carcinoma.

Study of Combination Therapy for Renal Cell Carcinoma
Clinical trial with combination therapies as a first line treatment in locally advanced or metastatic renal cell carcinoma.

Treatment Study for Renal Cell Carcinoma
An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered intuvax pre-nephrectomy followed by sunitinib post-nephrectomy, compared to sunitinib post-nephrectomy in mRCC.

Back to top of page

 

Leukemia

Acute Myeloid Leukemia Treatment Study
Expanded access of cytarabine:daunorubicin liposome injection for patients 60-75 years of age with secondary AML.

Chronic Lymphocytic Leukemia Treatment Study
A phase 3, randomized study to assess the efficacy and safety of ublituximab in combination with TGR-1202 compared to obinutuzumab in combination with chlorambucil in patients with chronic lymphocytic leukemia (CLL).

Clinical Study for Acute Myeloid Leukemia Patients with FLT3 Mutation
Clinical trial with combination therapies in AML with FLT3 mutation in patients not eligible for intensive induction chemotherapy.

Clinical Trial for Untreated MDS
Phase 1/2 study of vadastuximab talirine (SGN-CD33A) in combination with azacitidine in patients with previously untreated International Prognostic Scoring System (IPSS) intermediate-2 or high-risk myelodysplastic syndrome (MDS).

CMV-Seropositive Recipients Undergoing Hematopoietic Cell Transplant Treatment Study
A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the protective efficacy and safety of a therapeutic vaccine, ASP0113, in cytomegalovirus (CMV)-seropositive recipients undergoing allogeneic, hematopoietic cell transplant (HCT).

Late Stage Acute Myeloid Leukemia Study for Older Adults
A phase 3, multicenter, open-label, randomized study comparing the efficacy and safety of AG-221 (CC-90007) versus conventional care regimens in older subjects with late stage AML harboring an isocitrate dehydrogenase 2 mutation.

Newly Diagnosed Acute Myeloid Leukemia Treatment Study
A phase 3 study of quizartinib in combination with induction, consolidation, and maintenance chemotherapy, for subjects 18 to 75 years old with newly diagnosed FLT3-ITD (+) AML.

Study for Patients with Newly Diagnosed Acute Myeloid Leukemia
Midostaurin in adult patients with FLT3 mutated AML.

Treatment Study for Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Guadecitabine versus treatment choice in adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) previously treated with hypomethylating agents.

Treatment Study for Patients with Acute Myeloid Leukemia with FLT3 Mutation
A phase 3 open-label, multicenter, randomized study of ASP2215 versus salvage chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation.

Treatment Study for Patients with FLT3/ITD Acute Myeloid Leukemia in First Complete Remission
A phase 3 multi-center, randomized, double-blind, placebo-controlled trial of the FLT3 inhibitor gilteritinib (ASP2215) administered as maintenance therapy following induction/consolidation therapy for subjects with FLT3/ITD AML in 1st complete remission.

Treatment Study for Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase II part 2 expansion of oral rigosertib in combination with azacitidine in patients with myelodysplastic syndrome or acute myeloid leukemia.

Treatment Study for Patients with Myelofibrosis
A phase 2 study of INCB050465 in combination with ruxolitinib in subjects with myelofibrosis.

Using Rigosertib to Treat Myelodysplastic Syndrome Study
A phase III, international, randomized, controlled study of rigosertib versus physician’s choice of treatment in patients with myelodysplastic syndrome after failure of a hypomethylating agent.

Vadastuximab Talirine in New Untreated Acute Myeloid Leukemia
Vadastuximab talirine in new untreated AML.

Back to top of page

 

Liver, Biliary and Pancreatic Cancers

Hepatocellular Carcinoma Treatment Study
A study evaluating the overall survival rate of subjects with hepatocellular carcinoma (HCC) treated with TheraSphere and/or standard-of-care (SOC) sorafenib.

Initial Feasibility Study to Treat Pancreatic Cancer With a Planar LDR Source
Safety and efficacy of permanently implantable LDR CivaSheet® in combination with external beam radiation in the treatment of pancreatic cancer.

Patients With Selected Advanced Cancers Treatment Study
A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers.

Back to top of page

 

Lung and Chest Tumors

The ADAURA Study
A phase III, double-blind, randomized, placebo-controlled multi-center study to assess the efficacy and safety of AZD9291 versus placebo in patients with epidermal growth factor receptor mutation positive stage IB-IIIA non-small cell lung carcinoma, following complete tumor resection with or without adjuvant chemotherapy (ADAURA).

Completely Resected EGFR Mutant Non-Small Cell Lung Cancer Treatment Study
Randomized double blind placebo controlled study of erlotinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC).

Drug Treatment Study for Patients with Advanced Cancers
A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination With atezolizumab in patients with selected incurable cancers.

Investigational Drug Treatment Study for Patients with Lung Cancer
An open label, dose-finding and proof of concept study of the PD-L1 Probody™ therapeutic, CX-072, as monotherapy and in combination with Yervoy® (ipilimumab) or with Zelboraf® (vemurafenib) in subjects with advanced or recurrent solid tumors or lymphomas.

Locally Advanced Non-Small Cell Lung Cancer Treatment Study
Phase I/II trial of image-guided radiotherapy boost for locally advanced non-small cell lung cancer.

Non-Small Cell Lung Cancer Treated with nab-Paclitaxel (Abraxane) and Carboplatin Chemotherapy plus Necitumumab
A single-arm, multicenter, open-label, phase 2 study of nab-paclitaxel (abraxane) and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC).

Oral Targeted Therapy MGCD265 in NSCLC
Phase 2, parallel-arm study of MGCD265 in patients with locally advanced or metastatic non-small cell lung cancer with activating genetic alterations in mesenchymal-epithelial transition factor.

Patients With Selected Advanced Cancers Treatment Study
A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers.

PET and CT Radiation Therapy Study for Stage III Non-Small Cell Lung Cancer
Randomized phase II trial of individualized adaptive radiotherapy using during-treatment FDG-PET/CT and modern technology in locally advanced non-small cell lung cancer (NSCLC).

Radiation Therapy Treatment Study for Patients with Limited-Stage Small Cell Lung Cancer
Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide.

Small Cell Lung Cancer Treatment Study
Phase 1b/2a safety and pharmacokinetic study of G1T28 in patients with extensive stage small cell lung cancer (SCLC) receiving etoposide and carboplatin.

Study of Antroquinonol in Non-Squamous NSCLC
A single-arm, open-label, phase II trial evaluating the efficacy, safety and pharmacokinetics of antroquinonol in patients with stage IV (including pleural effusion) non-squamous NSCLC who have failed two lines of anti-cancer therapy.

Study of Whole-Brain Radiation Therapy in Treating Patients With Small Cell Lung Cancer
Randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer.

Surgically Resected ALK-Positive Early Stage Non-Small Cell Lung Cancer Treatment Study
A phase II double-blind trial for surgically resected early stage non-small cell lung cancer: Crizotinib versus placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein.

Treatment Study for Non-Small Cell Lung Cancer and Adenocarcinoma
A phase 1b open-label study of PEGylated recombinant human hyaluronidase (PEGPH20) combined with pembrolizumab in subjects with selected hyaluronan-high solid tumors.

Treatment Study for Patients with Advanced Malignancies
A phase 1, open-label, dose-escalation study of SEA-CD40 in adult patients with advanced malignancies.

Treatment Study for Patients with Advanced Solid Tumor Malignancies
Phase 1/1b study of MGCD516 in patients with advanced solid tumor malignancies.

Treatment Study for Patients with Non-Small Cell Lung Cancer, Melanoma or Colorectal Cancer
A phase 1b/2, open-label, dose escalation study of entinostat in combination with pembrolizumab in patients with non-small cell lung cancer, with expansion cohorts in patients with NSCLC, melanoma, and mismatch repair-proficient colorectal cancer.

Treatment Study for Patients with Stage IV Non-Small Cell Lung Cancer
A randomized two arm phase II trial of pembrolizumab alone or sequentially following single fraction non-ablative radiation to one of the target lesions, in previously treated patients with stage IV NSCLC.

Back to top of page

 

Lymphoma

Cutaneous T-Cell Lymphoma Treatment Study
A phase 3 multicenter, randomized, placebo-controlled study to determine the effect of topical SGX301 and fluorescent bulb-light irradiation for the treatment of cutaneous T-cell lymphoma.

Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype Treatment Study
A randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype.

Diffuse Large B-Cell Lymphoma Treatment Study
A phase 2 study of the combination of ublituximab + TGR-1202 and TG-1202 alone in patients with previously treated diffuse large B-cell lymphoma.

Follicular Lymphoma Treatment Study
Study of ibrutinib and rituximab in subjects whose follicular lymphoma has not been treated before.

Hodgkin Lymphoma Treatment Study
Study of pembrolizumab (MK-3475) in participants with relapsed or refractory classical Hodgkin lymphoma.

Mantle Cell Lymphoma Treatment Study
A phase 1b, multicenter, open-label study of ACP-196 in combination with bendamustine and rituximab in subjects with mantle cell lymphoma.

MYC-Associated B-Cell Lymphomas Treatment Study
Prospective, multi-center phase I/II trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated B-cell lymphomas.

Treatment Study for the Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma
A double blind, randomized, vehicle controlled, crossover study to evaluate the safety and efficacy of a topical lotion, for the relief of pruritus in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL).

Treatment Study for Patients with Advanced Malignancies
A phase 1, open-label, dose-escalation study of SEA-CD40 in adult patients with advanced malignancies.

Treatment Study for Patients with Cutaneous T-Cell Lymphoma
A clinical study to demonstrate safety and efficacy of E7777 (denileukin diftitox) in persistent or recurrent cutaneous T-cell lymphoma.

Treatment Study for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Treatment study of denintuzumab mafodotin (SGN-CD19A) plus RICE versus RICE alone for diffuse large B-cell lymphoma.

Back to top of page

 

Melanoma and Soft Tissue Cancers

Drug Treatment Study for Patients with Advanced Cancers
A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination With atezolizumab in patients with selected incurable cancers.

Melanoma Treatment Study
High dose interferon compared with pembrolizumab for patients with melanoma.

Patients With Selected Advanced Cancers Treatment Study
A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers.

Treatment Study For Patients With Advanced BRAFV600 Mutant Melanoma
Dabrafenib + trametinib followed by ipilimumab + nivolumab at progression or ipilimumab + nivolumab followed by dabrrafenib + trametinib at progression in patients with advanced BRAFV600 mutant melanoma.

Treatment Study for Patients with Non-Small Cell Lung Cancer, Melanoma or Colorectal Cancer
A phase 1b/2, open-label, dose escalation study of entinostat in combination with pembrolizumab in patients with non-small cell lung cancer, with expansion cohorts in patients with NSCLC, melanoma, and mismatch repair-proficient colorectal cancer.

Treatment Study for Patients with Unresectable Stage III or Stage IV Melanoma
Nivolumab plus ipilimumab plus sargramostin versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma.

Back to top of page

 

Myeloma

CMV-Seropositive Recipients Undergoing Hematopoietic Cell Transplant Treatment Study
A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the protective efficacy and safety of a therapeutic vaccine, ASP0113, in cytomegalovirus (CMV)-seropositive recipients undergoing allogeneic, hematopoietic cell transplant (HCT).

Maintenance Study For Patients With Residual Myeloma Post-Transplant
Phase II randomized trial of continuation of post-transplant maintenance with single-agent lenalidomide vs. consolidation/maintenance with ixazomib-lenalidomide-dexamethasone in patients with residual myeloma.

Multiple Myeloma Drug Treatment Study
A phase 3 study comparing daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in subjects with previously untreated multiple myeloma who are ineligible for high dose therapy (MAIA).

RVD Alone or Combined With Autologous Stem Cell Transplant in Myeloma
A randomized phase III study comparing conventional dose treatment using a combination of lenalidomide, bortezomib and dexamethasone (RVD) to high-dose treatment with peripheral stem cell transplant in the initial management of myeloma.

Study of Combination Therapies in Relapsed and Refractory Multiple Myeloma
Clinical trial with combination therapies in relapsed and refractory multiple myeloma.

Study Using VLX 1570 for Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma
Clinical trial with study drug and low-dose dexamethasone in relapsed or relapsed and refractory multiple myeloma.

Treatment Study for Patients with Multiple Myeloma
Pomalidomide/dexamethasone with or without elotuzumab for patients with multiple myeloma.

Treatment Study for Patients with Relapsed/Refractory Multiple Myeloma
Phase II clinical trial of melflufen in combination with low dose dexamethasone in patients with relapsed/refractory multiple myeloma who are refractory to pomalidomide and/or daratumumab.

Back to top of page

 

Pediatric Cancers

Acute Lymphoblastic Leukemia Treatment Study for Child Patients
Treatment of patients with newly diagnosed standard risk B-precursor acute lymphoblastic leukemia (ALL) for patients aged 365 days to 10 years.

Metastatic Ewing Sarcoma Treatment Study
Randomized phase II trial evaluating the addition of the IGF1R monoclonal antibody ganitumab (AMG 479, NSC#750008, IND#120449) to multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma.

Back to top of page

 

Prostate Cancer

Drug Treatment Study for Patients with Advanced Cancers
A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination With atezolizumab in patients with selected incurable cancers.

High Risk Prostate Cancer Hormone and Radiation Therapy Treatment Study
Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: A phase III randomized trial.

Metastatic Castration-Resistant Prostate Cancer Treatment Study
Phase Ib/II trial of pembrolizumab (MK-3475) combination therapies in metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-365).

Metastatic Hormone Sensitive Prostate Cancer Therapy Study
Study to determine if subjects with mHSPC will benefit from the addition of apalutamide to ADT.

Prostate Cancer Study
Phase 3, double blind trial, using investigational product in asymptomatic subjects with Gleason sum equal to or lesser than 7, metastatic androgen independent prostatic adenocarcinoma.

SBRT for Localized Prostate Cancer Study
A prospective evaluation of multi-parametric magnetic resonance imaging (mpMRI) guided stereotactic body radiation treatment for localized prostate cancer.

Treatment Study for Patients with Prostate Cancer
Phase II-III trial of adjuvant radiotherapy following radical prostatectomy with or without adjuvant docetaxel.

Treatment Study for Patients with Prostate Cancer with DNA Repair Defects
A randomized phase II trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair defects.

Back to top of page

 

Sarcomas

Non-Rhabdomyosarcoma Soft Tissue Sarcomas Treatment Study
Pazopanib neoadjuvant trial in non-rhabdomyosarcoma soft tissue sarcomas (PAZNTIS): A phase II/III randomized trial of preoperative chemoradiation or preoperative radiation plus or minus pPazopanib.

Patients With Selected Advanced Cancers Treatment Study
A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers.

Proton or Photon RT for Retroperitoneal Sarcomas Study
Phase I/II trial of pre-operative image guided intensity modulated proton radiation therapy (IMPT) or photon (IMRT) with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas.

Back to top of page

 

Testicular Cancer

Germ Cell Tumor Trial
Paclitaxel, ifosfamide, and cisplatin (Tip) with high-dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (Ti-ce).

Back to top of page

Advances in treatments and models of care for hematologic cancers are improving patients' prognoses and quality of life.

A Rush oncologist provides background on breast cancer, including who gets it and how it can be prevented.